Sinclair IS Pharma joins forces with Biocodex to crack new markets

Sinclair IS Pharma has signed a 10-year deal with Biocodex to expand its dermatology portfolio in Russia, Turkey and Europe's Benelux countries.

Biocodex, an independent French pharmaceutical company, will support in the importation and distribution of Sinclair products to wholesalers. The company will also facilitate in marketing, advertising, and promotion of commodities to clinicians and pharmacies.

Sinclair - a London-based pharmaceutical firm focused on treatments in dermatology, wound care and oncology support - expects the new partnership will help the organisation crack new markets.

Start your trial of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

"This partnership with Biocodex supports our growth strategy to create relationships with strong strategic partners and move our product portfolio into fast-growing, emerging markets" Chris Spooner, Chief Executive Officer of Sinclair, said.

"We already have a successful distribution partnership with Biocodex in Turkey, which provides the foundation for this new multi-product, multi-country arrangement."

Sinclair products which are part of the agreement include: Kelo-cote silicone-gel scar reduction range; Sculptra collagen stimulator for deep tissue regeneration; Papulex for acne; Bio-Taches for hyperpigmentation disorders; Atopiclair for atopic dermatitis; and Sebclair for the treatment of seborrhoeic dermatitis.

RD